Attovia Stock
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement.
Sign up for SecondMarket™ to view the market and buy or sell Attovia Stock
Buy + SellAttovia Funding
Sign up to gain insights into Attovia funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the DataDate | Financing Round | Amount | Price per share* | Valuation* |
---|---|---|---|---|
May 09, 2024 | Series B | 52.50M | ||
May 01, 2024 | Series B | 52.50M | ||
Jan 18, 2024 | Series A | 30.42M | ||
Jun 01, 2023 | Series A | 30.43M |
See Attovia Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Attovia Stock Valuation + Share Prices
View real-time Tape D™ data on Attovia stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get StartedAttovia Management Team
Attovia Major Investors
Learn More About Attovia Stock
Buy Attovia Stock
01Sell Attovia Stock
02Attovia Stock Price
03Attovia Stock Ticker Symbol
04Criteria to Sell Attovia Stock
05Criteria to Buy or Invest in Attovia Stock
06Attovia Stock Settlement
07Attovia IPO
08*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
Sign up for SecondMarket™ to view the market and buy or sell Attovia Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.